p-AKT Expression on Clinical Outcomes in Malignant Lymphoma
Study Details
Study Description
Brief Summary
PI3K(phosphatidylinositol 3-kinase)/AKT pathway is an important oncogenic signaling pathway. However, clinical information about the significance of p-AKT expression in malignant lymphoma is not fully understood yet. In this study, we investigated the overexpression of p-AKT and its prognostic implication in malignant lymphoma.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
Recently, among diverse oncogenic signaling pathways, a number of studies have focused on the significance of oncogenic PI3K/AKT (phophatidylinositol 3-kinase/serine-threonine kinase, also known as protein kinase B [PKB]) pathway. PI3K(phosphatidylinositol 3-kinase)/AKT pathway phosphorylates and activates AKT as phosphorylated AKT (p-AKT) and plays a critical role promoting malignant phenotype and has prognostic significance in various solid cancers.
However, a systematic approach on the impact of p-AKT overexpression on clinical outcomes has not been performed in malignant lymphoma.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
p-AKT p-AKT immunohistochemical staining,high p-AKT expression (upper quartile), low p-AKT expression (lower 3 quartiles) |
Other: p-AKT immunohistochemical staining
p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides
|
Outcome Measures
Primary Outcome Measures
- Difference of overall survival according to p-AKT status in malignant lymphoma [study entry]
Secondary Outcome Measures
- Subgroup analysis of overall survival according to histologic subtypes (GCB vs non GCB) [study entry]
Other Outcome Measures
- Subgroup analysis of overall survival according to International Prognostic Index risk groups [study entry]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
the patients were pathologically confirmed of malignant lymphoma, according to the World Health Organization classification;
-
the patients had adequate paraffin-embedded biopsy specimen or unstained slides for immunostaining of p-AKT.
Exclusion Criteria:
- Primary central nervous system lymphoma was excluded in this study
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Samsung Medical Center | Seoul | Korea, Republic of |
Sponsors and Collaborators
- Samsung Medical Center
Investigators
- Principal Investigator: Won Seog Kim, MD PhD, Samsung Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2013-01-047